Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA RSL3 cell line Investigators. Circulation. 1996;94:2807–16.PubMedCrossRef 8. Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral
regurgitation in chronic heart failure. Am J Cardiol. 1999;83:1201–5.PubMedCrossRef 9. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive Selleck Barasertib heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724–9.PubMedCrossRef 10. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817–25.PubMedCrossRef www.selleckchem.com/products/ITF2357(Givinostat).html 11. Morimoto S, Shimizu K, Yamada K, Hiramitsu S, Hishida H. Can beta-blocker therapy be withdrawn from patients with dilated cardiomyopathy? Am Heart J. 1999;138:456–9.PubMedCrossRef 12. Carson P, Ziesche S, Johnson G, Cohn
JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178–87.PubMedCrossRef PIK3C2G 13. Yancy CW. Heart failure in African Americans: a cardiovascular engima. J Card Fail. 2000;6:183–6.PubMedCrossRef 14. Thomas KL, East MA, Velazquez EJ, Tuttle RH, Shaw LK, O’Connor CM, et al. Outcomes by race and etiology of patients with left ventricular systolic dysfunction. Am J Cardiol. 2005;96:956–63.PubMedCrossRef 15. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA. 2006;103:11288–93.PubMedCrossRef
16. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:1358–65.PubMedCrossRef 17. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–55.PubMedCrossRef 18. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.PubMedCrossRef 19. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7.CrossRef 20.